DOPA Decarboxylase Modulates Tau Toxicity

Rebecca L Kow1, Carl Sikkema2, Jeanna M Wheeler3

  • 1Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle Division, Washington; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington.

Biological Psychiatry
|July 29, 2017
PubMed
Abstract

Insights

Loss of the DOPA decarboxylase (DDC) gene, bas-1, reduces tau toxicity in a C. elegans model. This finding suggests DDC suppression of tauopathy may involve levodopa and 5-hydroxytryptophan accumulation.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Tau protein aggregates are implicated in neurodegenerative diseases.
  • Loss of D2-family dopamine receptors previously showed promise in ameliorating tauopathy.

Purpose of the Study:

  • Investigate the mechanisms by which D2-family dopamine receptor loss alleviates tau toxicity.
  • Screen dopamine-related genes in C. elegans to identify factors influencing tau toxicity.

Main Methods:

  • Conducted a screen of 45 C. elegans mutations in dopamine-related genes.
  • Assessed the impact of mutations on tau transgene-induced behavioral defects.
  • Analyzed tau accumulation, phosphorylation, and neuron loss.

Main Results:

  • Identified DOPA decarboxylase (DDC) gene, bas-1, as a suppressor of tau toxicity.
  • Loss of bas-1 ameliorated behavioral deficits, reduced tau accumulation, and decreased neuron loss.
  • Other dopamine/serotonin synthesis genes did not affect tau toxicity but were necessary for bas-1 suppression.

Conclusions:

  • Loss of C. elegans DDC bas-1 significantly reduces tau-induced toxicity.
  • Suppression of tau toxicity by bas-1 may involve the accumulation of levodopa and 5-hydroxytryptophan.
  • D2-family dopamine receptor loss did not enhance bas-1 mediated suppression of tauopathy.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K